Oriana Nanni

7PUBLICATIONS
27CO-AUTHORS
Molecular targetsPacific Peoples life coursePredictive and prognostic markersClinical pharmacy and pharmacy practiceCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 04, 2024
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.

Francesco Schettini, Michela Palleschi, Francesca Mannozzi

|May 28, 2022
Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients.

Emanuela Scarpi, Oriana Nanni, Marco Maltoni

|Apr 08, 2022
Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study.

Isacco Montroni, Giampaolo Ugolini, Nicole M Saur

|Dec 21, 2021
An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study.

Alessandro Passardi, Patrizia Serra, Caterina Donati

|Oct 02, 2020
Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial.

Manlio Monti, Paolo Morgagni, Oriana Nanni

|Dec 12, 2018
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.

O Nanni, D Amadori, A De Censi

Pageof 2

Frequent Collaborators

2 joint publications

Flavia Foca

1 joint publications

Luca Saragoni

1 joint publications

Lorenza Rimassa

1 joint publications

Silvia Bozzarelli